A team committed to the development of a therapeutic portfolio in hearing loss
WHO ARE WE ?
Sensorion is a pioneering clinical-stage biotech company, dedicated to the development of innovative therapies to restore, treat and prevent within the field of hearing loss
15 years in pharmaceutical operations and strategic management
Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
Formerly Group Vice President, Rare Genetic Diseases, Shire
Géraldine Honnet, M.D.
Chief Medical Officer
20 years in clinical development and gene therapy
Formerly Director of Development, Genethon and Medical Director, Parexel International
Previously Senior Clinical Manager, Transgene
Bernd Schmidt
Chief Technical Officer
20 years’ experience in life sciences
CMC expert
Formerly Vice President Product Delivery at Quell Therapeutics and MPD Leader at GSK Stevenage
Laurene Danon
Chief Financial Officer
15 years of experience in investment banking and international equity capital markets.
Formerly Senior Banker at Jefferies and J.P. Morgan
Stéphanie Filipe
Head of the Project Management Office
15 years in therapeutic products development in Biotechs from bench to beside including gene and cell therapies
Formerly R&D Director at OTR3, Program Leader at Cellectis
Ph.D., Cellular Biology & Biochemistry
Laurent Désiré
Head of Preclinical Development
Over 15 years in pharmaceutical R&D and clinical development, especially in gene therapy and neuroscience
Formerly Head of Cellular and Molecular Biology unit at YposKesi, and R&D Executive Director at Diaxonhit and ExonHit
Ph.D., Biology of Aging
Christine Le Bec
Head of CMC Gene Therapy
25 years in production process development for gene therapy
Formerly Head of CMC analytical department, Genethon
Ph.D., Biochemistry and Analytical Chemistry
Valérie Salentey
Director of Regulatory Affairs & Quality Assurance
Over 15 years in Regulatory Affairs and Quality Assurance in Biologics and advanced therapies
Formerly headed Regulatory Affairs at Cytheris, Généthon, PPD, Neovacs
Doctor of Pharmacy (PharmD)
Rachel Cooper
Head of Audiology
Over 23 years in the hearing health industry
Formerly Global Professional Marketing Manager at Cochlear Ltd.
Doctor of Audiology (AuD), Cochlear Implant Specialty Certification (CISC), Pediatric Audiology Specialty Certification (PASC), Executive MBA
Khalil Barrage
Interim Chairman of the Board
Director, Representative of Invus
15 years of experience in portfolio management at The Olayan Group in New York
Managing Director for the Invus Group in New York and Board member of Protagenic and Celtaxsys
Nawal Ouzren
CEO and Director
15 years in pharmaceutical operations and strategic management
Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
Formerly Group Vice President, Rare Genetic Diseases, Shire
Julien Miara
Director, Representative of Invus
10 years of experience in investment, covering biotechnology among other sectors
Director at Invus
Cédric Moreau
Director representing Sofinnova Partners
18 years of experience in investment banking and in life sciences
Partner in the Crossover investment team at Sofinnova Partners
Natalie Berner
Director representing Redmile Group
Managing Director specializing in therapeutic products at Redmile
Former Research Associate at New York University School of Medicine
Bachelor’s degree in Community Health from Brown University and Certificate in Premedical Sciences from Columbia University
Member of two other boards: Redx Pharma and BioInvent
Eric de la Fortelle
Independent Director
10 years of experience as scientific researcher in biotechnology, CEO and member of several Boards
Venture Partner at Seventure Partners
John Furey
Independent Director
20 years of experience as CEO and Chief Operating Officer in pharmaceutical societies
CEO of Imvax
Non Executive Director at Adaptimmune
Aniz Girach
Independent Director
M.D., over 22 years’ experience in the pharma industry
CMO at ProQR Therapeutics
Member of three Scientific Advisory Boards
Florian Reinaud
Board Observer Redmile Group
Special Advisor Europe for Redmile Group
20 years experience in Healthcare Innovation and Capital Investment
Former emergency physician in the UK’s National Health Service
MD., awarded with Distinction from Imperial College London and holds a BA(hons) in Physiology from the University of Oxford
Board Member of Sensome
Federico Mingozzi, Ph.D.
Non-Executive Director
More than 25 years experience in gene therapy, immunology, as well as biochemistry and
molecular biology
Previously Chief Science and Technology at Spark Therapeutics
He holds a bachelor’s degree in biology and a Ph.D. in biochemistry and molecular biology from the
University of Ferrara in Italy, and a M.B.A. from Drexel University.
Pr Christine Petit
Chair of the Scientific Advisory Board
Chair of Genetics and Cellular Physiology, Professor at College de France and at Institut Pasteur (Paris)
Head of the Laboratory of Genetics and Physiology of Hearing at Institut Pasteur
Managing Director of the French Hearing Institute
Member of the French and American Sciences Academies and the American Medical Academy
Pr Alain Fischer
Professor at College de France
Former director and founding member of the Institute for Genetic Diseases (Imagine)
Former director of the pediatric immuno-hematology department at Necker Hospital
Dr Robert Dow
More than 37 years of experience in the pharmaceutical and biotech industry
Former Chief Medical Officer at PPD Inc.
Substantial experience across therapeutic areas from pre-clinical to Phase 3 development
Pr Paul Avan
Physicist and Medical Doctor in Biophysics
Head of the Center for Research and Innovation in Human Audiology at Hearing Institute (Paris)
Designed original objective methods of exploration of the cochlea and auditory pathways
Dr. Diane Lazard
ENT Surgeon and former Head of Clinic at AP-HP
Principal Associate Investigator at the Hearing Institute (Paris)
Currently pursuing research on deciphering language processing variability in deafness
Dr. Hernán López-Schier
Senior Group Leader and Research Unit Director at the Helmholtz Center in Munich
Currently pursuing research on fundamental sensory biology and sensory dysfunction
His group was the first to visualize the regeneration of mechanosensory hair cells in their natural context
04 67 20 77 30
